Conjunctivitis Treatment Market Segmentation:
Drug Class Segment Analysis
The global conjunctivitis treatment market is segmented and analyzed for demand and supply by drug class into antibiotics, antiviral, antiallergic, artificial tears, and others. Out of these types of segments, the antiallergic segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the increasing use of antiallergic drugs in allergic reactions as these drugs provide faster relief and recovery in such diseases, along with the growing prevalence of allergies among people, especially those who are prone to seasonal allergies. For instance, allergic conjunctivitis or allergic eye issue was seen in 40% of people in the United States in 2020.
Disease Type Segment Analysis
The global conjunctivitis treatment market is also segmented and analyzed for demand and supply by disease type into bacterial conjunctivitis, chemical conjunctivitis, viral conjunctivitis, and allergic conjunctivitis. Amongst these segments, the allergic conjunctivitis segment is expected to garner a significant share. The segment is anticipated to grow owing to the surging prevalence of allergic conjunctivitis. In addition to this, an upsurge in the novel product launches for the effective treatment of this disease is another major factor that is anticipated to propel the market growth. On the other hand, the viral conjunctivitis segment is projected to witness a moderate CAGR during the forecast period, owing to the surge in contagious virus spread as a result of the common cold.
Route of Administration Segment Analysis
On the other hand, the global conjunctivitis treatment market is also segmented and analyzed for demand and supply by route of administration into oral, and topical. Amongst these two segments, the topical segment is projected to grasp a notable market share. The growth of the segment can be attributed to the formulation and launch of novel drugs that can be easily used and deliver effective treatment. For instance, in March 2022, Visus Therapeutics Inc. announced the commencement of the first of two important phases 3 trials (BRIO-I and BRIO-II) for its flagship asset, BRIMOCHOL PF, a topical preservative-free ophthalmic liquid for the treatment of presbyopia.
Our in-depth analysis of the global market includes the following segments:
|
By Drug Class |
|
|
By Disease Type |
|
|
By Route of Administration |
|
|
By End-User |
|
